VERTEX PHARMACEUTICALS INC / MA Deferred Income Tax Expense (Benefit)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Deferred Income Tax Expense (Benefit) of -$510.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA deferred income tax expense (benefit) for the quarter ending 2020-12-31 was $486.30M.
- VERTEX PHARMACEUTICALS INC / MA deferred income tax expense (benefit) for the quarter ending 2020-06-30 was -$209.00M.
- VERTEX PHARMACEUTICALS INC / MA deferred income tax expense (benefit) for fiscal 2025 was -$510.80M.
- VERTEX PHARMACEUTICALS INC / MA deferred income tax expense (benefit) for fiscal 2024 was -$348.80M.
- VERTEX PHARMACEUTICALS INC / MA deferred income tax expense (benefit) for fiscal 2023 was -$536.50M.
- VERTEX PHARMACEUTICALS INC / MA deferred income tax expense (benefit) for fiscal 2022 was -$275.90M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 3 month as first filed | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$510.80M 10-K · filed 2026-02-13 | ||||
| 2024-12-31 | -$348.80M 10-K · filed 2026-02-13 | ||||
| 2023-12-31 | -$536.50M 10-K · filed 2026-02-13 | ||||
| 2022-12-31 | -$275.90M 10-K · filed 2025-02-13 | ||||
| 2021-12-31 | -$154.60M 10-K · filed 2024-02-15 | ||||
| 2020-12-31 | $486.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $277.30M 10-K · filed 2023-02-10 | $277.34M 10-K · filed 2021-02-11 | ||
| 2020-09-30 | -$209.00M 10-Q · filed 2020-10-30 | ||||
| 2020-06-30 | -$209.00M 10-K · filed 2021-02-11 | -$187.00M 10-Q · filed 2020-07-31 | |||
| 2019-12-31 | $167.40M 10-K · filed 2022-02-09 | $167.39M 10-K · filed 2020-02-13 | |||
| 2018-12-31 | -$1.51B 10-K · filed 2021-02-11 | ||||
| 2017-12-31 | -$127.48M 10-K · filed 2020-02-13 | ||||
| 2016-12-31 | $16.86M 10-K · filed 2019-02-13 | ||||
| 2015-12-31 | $298.00K 10-K · filed 2018-02-15 | ||||
| 2014-12-31 | $282.00K 10-K · filed 2017-02-23 | ||||
| 2013-12-31 | -$127.59M 10-K · filed 2016-02-16 | -$280.37M 10-K · filed 2014-02-11 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-02-13 | $36.66M 10-K · filed 2013-03-01 | |||
| 2011-12-31 | -$11.10M 10-K · filed 2014-02-11 | ||||
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |